Tumor-derived MLCs expressed mesenchymal glioma markers, such as CD44, VEGFA, CHI3L1, HIF1A, and CA9 (Fig. 1b, c), whereas tumor-derived IPCs upregulated cell cycle genes (GOE adjusted p value \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$=2\times {10}^{-97}$$\end{document}=2×10−97), such as TOP2A, MKI67, and ASPM (Fig. 1b). The gene discussed is TOP2A; the disease is glioma.